TOTUM•854 is a unique patented combination of plant extracts, specifically designed to reduce arterial blood pressure in people with mild to moderate elevated blood pressure, a risk factor for cardiovascular disease.
TOTUM•854 is a unique patented combination of plant extracts, specifically designed to reduce arterial blood pressure in people with mild to moderate elevated blood pressure, a risk factor for cardiovascular disease.
Arterial hypertension (AHT) is the world’s most prevalent chronic disease and the leading cause of premature death. It affects all countries, whether rich or poor. Over time, AHT weakens the arteries and promotes the onset of serious diseases, predominantly heart attacks, strokes, peripheral arterial diseases and kidney failure. It is the primary cardiovascular risk factor in the world.
1.13 billion people worldwide suffered from arterial hypertension in 2015. 30% to 45% of adults were hypertensive.
140/90 mmHg is the defined threshold for arterial hypertension in Europe. In the United States, the threshold value starts at 130/80 mmHg.
TOTUM•854 is a unique patented combination of plant extracts, designed to reduce blood pressure in people with low to moderate elevated blood pressure, a risk factor for cardiovascular diseases.
TOTUM•854 could provide a new opportunity on a global market of more than one billion people, as no non-drug product has shown solid clinical evidence to date or received a health claim authorization relative to the reduction of blood pressure.
Led in two different in vivo models, predictive of human physiology, the preclinical studies showed that TOTUM•854 prevented arterial hypertension. These preclincal data were obtained thanks to a partnership with the experimental unit of the Cardiovascular Pharm-Ecology Lab (LaPEC) of Avignon University.
They were presented in April 2021 at the Annual Joint Meeting of European Society of Hypertension (ESH) and International Hypertension Society (ISH).
In this classic model of hypertension, TOTUM•854 prevented the onset of hypertension, over 3 weeks, compared to L-NAME only. This significant preventive was shown on:
– the raise of dystolic blood pressure (SBP);
– the raise of diastolic blood pressure (DBP).
In this model of spontaneous hypertension, TOTUM•854 showed a positive effect, delaying the onset of arterial hypertension. An acute effect was also recorder after and oral intake of one dose of TOTUM•854.
The TOTUM•854 clinical development program includes three clinical studies, whose results will be required in Europe and the United States for health claim applications in the reduction of blood pressure, which is a risk factor for cardiovascular disease:
Valbiotis has adopted a global strategy to protect its intellectual property: patent applications have been filed for TOTUM•854 in 61 countries, including key markets: Europe, USA, Canada, China, Russia, Japan, Brazil and Australia.
Patents have already been issued in 48 countries, including in the USA, Europe (39 countries), China and Russia, providing a very high level of protection.